Tumor-related factors that lead to chemotherapy resistance in Hispanic women make them more likely to die from breast cancer than non-Hispanic whites.
Latest Conference Articles
Dr. Debu Tripathy from USC Norris Comprehensive Cancer Center Discusses the AVEREL Bevacizumab Trial Results
Advertisement
The CLEOPATRA trial marks the first time that dual inhibitors have demonstrated value in the treatment of HER2-positive metastatic breast cancer.
Dr. Gabriel Hortobagyi from the MD Anderson Cancer Center Discusses the BOLERO-2 Trial
The BOLERO-2 trial suggests that adding everolimus to hormonal therapy can overcome resistance in patients whose disease progressed.
A large study of HER2+ breast cancer patients shows that obese patients had worse outcomes than normal weight or overweight patients.
Advertisement
Dr. Edith Perez from the Mayo Clinic Cancer Center Discusses the CLEOPATRA Pertuzumab Trial
The results of 2 studies likely to have a significant impact upon the treatment of women with metastatic breast cancer.
Dr. Benjamin Smith from MD Anderson Cancer Center Discusses the Brachytherapy Breast Cancer Trial
A new 12-gene assay for predicting risk of recurrence for patients with ductal carcinoma in situ (DCIS).
Dr. Lawrence Solin from Einstein Medical Center Discusses the DCIS Score Recurrence Test
It may be possible to predict which women with HR+ invasive breast cancer will experience recurrence by using a series of gene expression profiles.
Pictures from The 2011 European Multidisciplinary Cancer Congress (EMCC) in Stockholm, Sweden
Radiotherapy can be given between or during chemotherapy cycles, rather than sequentially, for women with early breast cancer.
Aflibercept added to FOLFIRI chemotherapy improved PFS and OS in previously treated patients with metastatic colorectal cancer.
T-DM1 extended progression-free survival by 40% in HER2+ metastatic breast cancer and was less toxic, compared with standard therapy.
Panitumumab + chemo improves OS and PFS in patients with metastatic carcinoma of the head and neck that were negative for HPV.
Investigational drug that emits alpha radiation shows significant improvement in overall survival.
Patients with liver metastases from uveal melanoma had improved survival after treatment with percutaneous hepatic perfusion (PHP).
Two studies enhance understanding of risk factors for prostate cancer.
The 16th ECCO, 36th ESMO, 30th ESTRO Congresses from the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden, September 23-27.
American Society of Clinical Oncology (ASCO) 2011 Annual Meeting Daily Picture Slideshow
Cabozantinib (XL184), a novel tyrosine kinase inhibitor, caused the deaths of 6 patients in a phase II clinical trial.
Dr. Vogelzang from the Comprehensive Cancer Centers of Nevada discusses mortalities in cabozantinib trial.
Women who present with BRCA1 and BRCA2 mutation face an increased risk of breast and ovarian cancer.
Dr. Infante from Sarah Cannon Research Institute Talks About BRAF Mutation Testing
Phosphatase and tensin homolog (PTEN)-positive breast cancer can be treated with trastuzumab (Herceptin) as effectively as PTEN-negative breast cancer
American Society of Clinical Oncology 2011 Annual Meeting Picture Slideshow Day Four
Axitinib demonstrated significantly better progression-free survival (PFS) compared with sorafenib
Luminal A genetic signature in node-negative, estrogen receptor- (ER-) positive breast cancer predicts a very high disease-free survival rate
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5